Skip to main content
. 2023 Aug 4;15(15):3967. doi: 10.3390/cancers15153967

Table 3.

Summary of planned or ongoing registered trials of immune checkpoint inhibitor in combination with other immunomodulating agents.

NCT Number ICI Other Immunotherapy
NCT04940286 Durvalumab Oleclumab (CD-73 inhibitor)
NCT03727880 Pembrolizumab Defactinib (FAK inhibitor)
NCT03767582 Nivolumab BMS-813160 (CCR2/CCR5 inhibitor), GVAX